The present disclosure provides co-crystals of a lithium benzoate compound and a co-former compound of Formula (I) ##STR00001##
Also provided herein are methods of preparing the co-crystals and uses thereof in treating and/or reducing the risk for a neuropsychiatric disorder (e.g., schizophrenia, psychotic disorders, depressive disorders, bipolar disorders, or neurodegenerative disorders).

The present invention relates to a conjugate salt of N,N-dimethylglycine with metal and organic acid, and a preparation method and use thereof. The conjugate salt of N,N-dimethylglycine with metal and organic acid has a following structural formula: [(CH.sub.3).sub.2NCH.sub.2COO].sub.nM.[Organic acid], wherein, n is 1 or 2; M is selected from an alkali metal ion or a divalent metal ion; the organic acid is selected from an organic polyacid, a C.sub.2-C.sub.18 linear fatty acid or an aromatic acid. The conjugate salt of N,N-dimethylglycine with metal and organic acid is a conjugate acid salt formed by introducing another organic acid with a hydrophobic group into the salt of N,N-dimethylglycine and a metal ion, so as to modify the hygroscopicity of N,N-dimethylglycine by decreasing the affinity of the salt toward water molecules in the air, or decreasing the affinity or attraction of molecular aggregates formed through crystalline behavior of the salt toward water molecules in the air.

The present invention discloses a polyvalent metal ion compound salt of N,N-dimethylglycine and organic acid or a solvate thereof, and use thereof in preparing novel feed additives and feed; the present invention also discloses a composition comprising the polyvalent metal ion compound salt of N,N-dimethylglycine and organic acid or the solvate thereof. The polyvalent metal ion compound salt of N,N-dimethylglycine and organic acid or the solvate thereof provided by the present invention has improvement effect on animal product performance such as improving animal weight gain and reducing feed conversion ratio, showing effects similar to or higher than that of sodium N,N-dimethylglycinate.

Disclosed herein are forms of L-ornithine phenyl acetate and methods of making the same. A crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.

Disclosed herein are forms of L-ornithine phenyl acetate and methods of making the same. A crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.

A resist composition comprising a base polymer and a quencher containing a sulfonium salt having an iodized benzene ring offers a high sensitivity, minimal LWR and improved CDU independent of whether it is of positive or negative tone.

A resist composition comprising a base polymer and a quencher containing a sulfonium salt having an iodized benzene ring offers a high sensitivity, minimal LWR and improved CDU independent of whether it is of positive or negative tone.

Disclosed herein are forms of L-ornithine phenyl acetate and methods of making the same. A crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.

Disclosed herein are forms of L-ornithine phenyl acetate and methods of making the same. A crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.

The present disclosure relates to free base and salt crystals of 2-(4-acetylbenzyl)-3-((4-fluorophenyl)amino)-5,7,7-trimethyl-7,8-dihydro-2H-imidazo[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5H)-one, composition comprising the same and the method of making and using such free base and salt crystals.